Table 2. Comparison of characteristics at last follow-up after FTY treatment between Gr-4 lymphopenia and non-Gr-4 lymphopenia.
| Characteristic | All (n=69) | Gr-4 lymphopenia (n=7) | Non-Gr-4 lymphopenia (n=62) | p | |
|---|---|---|---|---|---|
| Duration of FTY treatment, months | 32.3±4.7 | 28.5±29.6 | 32.7±40.9 | 0.921 | |
| Posttreatment ALC, /μL | 669.4±304.7 | 330±84.7 | 690.0±263.9 | <0.001 | |
| Posttreatment EDSS score | 2 [0–6.5] | 1 [0–3] | 2 [0–6.5] | 0.077 | |
| Patients with worsening EDSS score | 9 (13) | 0 (0) | 9 (14.5) | 0.582 | |
| Posttreatment ARR | 0.04±0.30 | 0.06±0.20 | 0.04±0.30 | 0.303 | |
| Patients with no radiological activity | 56 (81.2) | 5 (71.4) | 51 (82.3) | 0.609 | |
| Patients without clinical relapse | 65 (94.2) | 6 (85.7) | 59 (95.2) | 0.355 | |
| Patient with NEDA | 55 (79.7) | 5 (71.4) | 50 (80.6) | 0.624 | |
| Patients with cessation of FTY | 10 (14.5) | 1 (14.3) | 9 (14.5) | >0.999 | |
| Dose | |||||
| Full dose | 49 (71) | 4 (57.1) | 45 (72.6) | ||
| Transient EOD | 5 (7.2) | 1 (14.3) | 4 (6.5) | ||
| Transient suspension | 2 (2.9) | 0 (0) | 2 (3.2) | ||
| Maintained EOD | 3 (4.3) | 1 (14.3) | 2 (3.2) | ||
| Interrupting FTY and switching to other DMT | 10 (14.5) | 1 (14.3) | 9 (14.5) | ||
Data are mean±SD, n (%), or median [range] values.
ALC, absolute lymphocyte count; ARR, annualized relapse rate; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; EOD, every other day; FTY, fingolimod; Gr, grade; IgG, immunoglobulin G; NEDA, no evidence of disease activity; SD, standard deviation; VZV, varicella zoster virus.